Learn more about WIPO Re:Search members by viewing their detailed profiles.
WIPO Re:Search Resource Platform terms and conditions of use
Learn more about WIPO Re:Search members by viewing their detailed profiles.
WIPO Re:Search Resource Platform terms and conditions of use
Choose one option to export the data.
PPT
Members
The University of Toronto is a research-intensive university which has been awarded $1.2 billion in research...
Home to world-renowned scientists and labs focused on infectious disease drug discovery, The University of...
Established in 1915, The Walter and Eliza Hall Institute of Medical Research (WEHI) is Australia’s oldest...
The Walter Reed Army Institute of Research (WRAIR) was founded in 1893 as the Army Medical School and today is...
Researchers at AAU’s Aklilu Lemma Institute of Pathobiology undertake a variety of research activities...
The Biomedical Research Institute (BRI) is a nonprofit organization committed to improving global health. BRI...
Collaborations
Resistance to current antimalarial drugs is a serious problem. There is a critical need for new medications with novel mechanisms of action. Preliminary data from Dr. Gilbert and others suggested that a certain class of compounds might have antimalarial activity. BVGH connected Dr. Gilbert with scientists at Eisai, who shared proprietary compounds of that class for Dr. Gilbert’s malaria drug discovery program.
A promising series of antimalarial compounds developed in Dr. Van Voorhis’ laboratory, termed bumped kinase inhibitors (BKIs), blocks transmission of malaria parasites from infected humans to mosquitos. BVGH connected Dr. Van Voorhis with scientists at GSK’s Malaria Discovery Performance Unit (DPU) in Tres Cantos, Spain, who re-profiled several BKIs through a battery of kinase/kinome tests to characterize their safety and activity.
Dr. Taylor leaded the Anti-Wolbachia Consortium (A·WOL), whose aim was to develop novel drugs against onchocerciasis and lymphatic filariasis by targeting Wolbachia, the nematodes’ essential endosymbiont. The A·WOL team partnered with AstraZeneca to develop a high-content screening assay for Wolbachia, which was used in screening 1.3 million compounds from AstraZeneca's in-house library that might be re-proposable against onchocerciasis and lymphatic filariasis.
Dr. Wyatt leads the Drug Discovery Unit at the University of Dundee, and was interested in repurposing GSK-3 beta inhibitors for treating kinetoplastid diseases. BVGH connected Dr. Wyatt with AstraZeneca, who shared a targeted library of nine GSK-3 inhibitors with him. Dr. Wyatt tested the inhibitors for activity against T. cruzi, T. brucei, and Leishmania. A compound with interesting activity against L. donovani was identified and AstraZeneca provided 1000 analogues for testing in the University of Dundee assays. Structure release was agreed for 10 of the most promising analogues and any available PK information was provided by AstraZeneca, as well as kinase panel selectivity data. One compound had a promising profile and AstraZeneca provided 200mg of this compound to allow an in vivo efficacy study for visceral leishmaniasis at the University of Dundee. While this compound showed some level of efficacy it also had toxic side effects. Currently this program is progressing at the University of Dundee with its main aim improving the selectivity of the series.
Dr. Liotta had developed nucleoside analogs for a variety of viral diseases and was interested in assessing their promise as new therapies against several DNA and RNA viral pathogens, including dengue, Rift Valley fever, Ebola, influenza, adenovirus, and human herpesviruses. However, he did not have the capacity in his laboratory to do multiple viral family screenings. BVGH connected Dr. Liotta and colleagues with Drs. Cassetti and Tseng, who arranged for NIH-funded contractors to test the compounds in vitro for efficacy against many DNA and RNA viral families. These projects have been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services, under contract numbers: HHSN272201100008I, HHSN272201100013I, HHSN272201100016I, and HHSN272201100019I.
A research team from Caltech designed a low-cost microfluidic qPCR instrument and solicited expert input on tailoring the platform for field diagnosis of tuberculosis. BVGH connected the Caltech investigators with a diagnostics expert at PATH to provide advice regarding multiple aspects of technology development.
Assets